{"title":"Pharmacotherapy for the management of overweight and obesity.","authors":"Patrice Forner, Samantha Hocking","doi":"10.31128/AJGP-09-24-7411","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Lifestyle intervention is the mainstay of obesity management; however, behavioural modification alone produces only modest results and attempts to create a negative energy balance are offset by a biological response to maintain weight. Pharmacotherapy is indicated as an adjunct for those living with obesity (body mass index [BMI] ≥30 kg/m2) or those who are overweight (BMI ≥27 kg/m2) with a least one weight-related complication.</p><p><strong>Objective: </strong>This article provides an update on pharmacotherapy for the management of overweight and obesity.</p><p><strong>Discussion: </strong>Pharmacotherapy is a useful adjunct for the treatment of obesity and obesity-related comorbidities. When considering pharmacotherapy, thought must be given to efficacy, contraindications, potential side effects, cost and duration of treatment.</p>","PeriodicalId":54241,"journal":{"name":"Australian Journal of General Practice","volume":"54 4","pages":"196-201"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Journal of General Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31128/AJGP-09-24-7411","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Lifestyle intervention is the mainstay of obesity management; however, behavioural modification alone produces only modest results and attempts to create a negative energy balance are offset by a biological response to maintain weight. Pharmacotherapy is indicated as an adjunct for those living with obesity (body mass index [BMI] ≥30 kg/m2) or those who are overweight (BMI ≥27 kg/m2) with a least one weight-related complication.
Objective: This article provides an update on pharmacotherapy for the management of overweight and obesity.
Discussion: Pharmacotherapy is a useful adjunct for the treatment of obesity and obesity-related comorbidities. When considering pharmacotherapy, thought must be given to efficacy, contraindications, potential side effects, cost and duration of treatment.
期刊介绍：
The Australian Journal of General Practice (AJGP) aims to provide relevant, evidence-based, clearly articulated information to Australian general practitioners (GPs) to assist them in providing the highest quality patient care, applicable to the varied geographic and social contexts in which GPs work and to all GP roles as clinician, researcher, educator, practice team member and opinion leader. All articles are subject to peer review before they are accepted for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
